Iclusig

Chemical Nameponatinib
Dosage FormTablet (oral; 10mg, 15mg, 30mg, 45mg)
Drug ClassKinase inhibitors
SystemBlood
CompanyTakeda Pharmaceutical Company Limited
Approval Year2012

Indication

  • For the treatment of chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors in adult patients.
  • For the treatment of accelerated phase (AP) or blast phase (BP) CML or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated in adult patients.
  • For the treatment of T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL in adult patients.
Last updated on 5/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Iclusig (ponatinib) Prescribing Information2020Millennium Pharmaceuticals, Inc., Cambridge, MA
Document TitleYearSource
Chronic myeloid leukemia, version 2.2021.2020Journal of the National Comprehensive Cancer Network
Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.2017Annals of Oncology